NASDAQ:BLRX BioLineRx (BLRX) Stock Price, News & Analysis $2.21 +0.01 (+0.45%) Closing price 10/8/2026 03:59 PM EasternExtended Trading$2.23 +0.02 (+0.90%) As of 10/8/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About BioLineRx Stock (NASDAQ:BLRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioLineRx alerts:Sign Up Key Stats Today's Range$2.17▼$2.3150-Day Range$2.20▼$3.0052-Week Range$2.15▼$4.50Volume18,372 shsAverage Volume14,591 shsMarket Capitalization$11.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview BioLineRx Ltd. (NASDAQ: BLRX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s lead product is motixafortide, a CXCR4 antagonist designed to mobilize hematopoietic stem cells and alter the tumor microenvironment. In the United States, motixafortide is marketed under the brand name APHEXDA for use in combination with filgrastim to mobilize stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma. The product received approval from the U.S. Food and Drug Administration in 2023. BioLineRx continues to evaluate motixafortide in additional oncology applications, including investigational combination treatments intended to improve immune-cell access to solid tumors such as pancreatic cancer. Founded in Israel, the company operates internationally and has been led by Chief Executive Officer Philip Serlin.AI Generated. May Contain Errors. Read More BioLineRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreBLRX MarketRank™: BioLineRx scored higher than 6% of companies evaluated by MarketBeat, and ranked 863rd out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBioLineRx has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBioLineRx has only been the subject of 1 research reports in the past 90 days.Read more about BioLineRx's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioLineRx are expected to grow in the coming year, from ($1.57) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLineRx is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLineRx is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLineRx has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioLineRx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.04% of the float of BioLineRx has been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 6.05.Change versus previous monthShort interest in BioLineRx has recently increased by 7.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioLineRx does not currently pay a dividend.Dividend GrowthBioLineRx does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for BioLineRx this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for BLRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioLineRx insiders have not sold or bought any company stock.Percentage Held by Insiders1.10% of the stock of BioLineRx is held by insiders.Percentage Held by Institutions1.56% of the stock of BioLineRx is held by institutions.Read more about BioLineRx's insider trading history. Receive BLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BLRX Stock News HeadlinesBioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education DayOctober 8 at 7:00 AM | prnewswire.comCritical Review: CRISPR Therapeutics (NASDAQ:CRSP) vs. BioLineRx (NASDAQ:BLRX)October 6 at 4:15 AM | americanbankingnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. | The Oxford Club (Ad)Comparing Nuvation Bio (NYSE:NUVB) & BioLineRx (NASDAQ:BLRX)September 28, 2026 | americanbankingnews.comBioLineRx Shareholders Approve Board, Capital and Compensation Moves at 2026 AGMSeptember 24, 2026 | tipranks.comBioLineRx And Hemispherian To Present GLIX1 Data At EANO 2026; Stock UpSeptember 10, 2026 | rttnews.comBioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro ...September 10, 2026 | markets.ft.comBioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)September 10, 2026 | prnewswire.comSee More Headlines BLRX Stock Analysis - Frequently Asked Questions How have BLRX shares performed this year? BioLineRx's stock was trading at $2.77 at the beginning of 2026. Since then, BLRX shares have decreased by 20.2% and is now trading at $2.21. How were BioLineRx's earnings last quarter? BioLineRx Ltd. (NASDAQ:BLRX) issued its quarterly earnings results on Friday, August, 28th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.62. The biotechnology company had revenue of $0.29 million for the quarter, compared to analysts' expectations of $0.50 million. BioLineRx had a negative trailing twelve-month return on equity of 34.80% and a negative net margin of 502.08%. Read the conference call transcript. When did BioLineRx's stock split? Shares of BioLineRx reverse split on Thursday, January 30th 2025.The 1-40 reverse split was announced on Friday, January 17th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 29th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of BioLineRx? Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioLineRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioLineRx investors own include Savara (SVRA), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI) and Tesla (TSLA). Company Calendar Last Earnings8/28/2026Today10/09/2026Next Earnings (Estimated)11/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 2 days ago, BLRX's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BLRX CIK1498403 Webwww.biolinerx.com Phone(728) 642-9100Fax972-8642-9101Employees24Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.17 million Net Margins-502.08% Pretax Margin-728.45% Return on Equity-34.80% Return on Assets-18.27% Debt Debt-to-Equity Ratio0.13 Current Ratio1.20 Quick Ratio1.04 Sales & Book Value Annual Sales$1.18 million Price / Sales9.33 Cash FlowN/A Price / Cash FlowN/A Book Value$5.36 per share Price / Book0.41Miscellaneous Outstanding Shares4,980,000Free Float4,923,000Market Cap$11.01 million OptionableOptionable Beta1.61 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BLRX) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLRX Stock Alerts